Karger Kompass Onkologie最新文献

筛选
英文 中文
Neuroendokrine Tumoren: Wirksamkeit der Kombinations-Chemotherapie bestätigt 内分泌学:组合治疗的有效性得到确认
Karger Kompass Onkologie Pub Date : 2019-12-01 DOI: 10.1159/000503083
M. Stahl
{"title":"Neuroendokrine Tumoren: Wirksamkeit der Kombinations-Chemotherapie bestätigt","authors":"M. Stahl","doi":"10.1159/000503083","DOIUrl":"https://doi.org/10.1159/000503083","url":null,"abstract":"Background: Capecitabine and temozolomide combination (CAPTEM) is associated with high response rates in patients with advanced neuroendocrine neoplasms (NENs). We evaluated the real-world activity and safety of CAPTEM from 3 NEN centers. Methods: Clinicopathological characteristics and outcomes of patients treated with CAPTEM for bulky or progressive disease (PD) were retrospectively analyzed. Results: Seventy-nine patients with gastroenteropancreatic (grades 1 - 2 [n = 38], grade 3 [n = 24]) and lung/thymic (n = 17) NENs were included. Median treatment duration was 12.1 months (range 0.6 - 55.6). Overall, partial responses (PRs) occurred in 23 (29.1%), stable (SD) in 24 (30.4%), and PD in 28 (35.4%) patients. Median progression-free survival (PFS) and overall survival (OS) were 10.1 (6 - 14.2) and 102.9 months (43.3-162.5), respectively. On univariate analysis, NENs naive to chemotherapy and low Ki67 were associated with favorable responses (partial response [PR] + SD; p = 0.011 and 0.045), PFS (p < 0.0001 and 0.002) and OS (p = 0.005 and 0.001). Primary site (pancreas and lung/thymus) was also a significant prognostic factor for PFS (p < 0.0001) and OS (p < 0.0001). On multivariate analysis, gastrointestinal and unknown primary NENs (hazard ratio [HR] 0.3, 95% CI 0.1 - 0.8, p = 0.009 and p = 0.018) and prior surgery (HR 2.4, 95% CI 11 - 4.9, p = 0.021) were independent prognostic factors for PFS. Ki-67 was a poor predictor for favorable response in receiver operating characteristic analysis (area under the curve 0.678). Safety analysis of CAPTEM indicated rare events of serious (grades 3 - 4) toxicities (n = 4) and low discontinuation rates (n = 8) even in patients with prolonged administration ( > 12 months). Conclusions: CAPTEM treatment can be an effective and safe treatment even after prolonged administration for patients with NENs of various sites and Ki67 labeling index, associated with significant favorable responses and PFS.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124855492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Komplementärmedizin: Auch bei Umfragen muss die Methodik im Detail berichtet werden 互补医学:即使是调查中,方法也需要详细阐述
Karger Kompass Onkologie Pub Date : 2019-12-01 DOI: 10.1159/000504457
C. Witt
{"title":"Komplementärmedizin: Auch bei Umfragen muss die Methodik im Detail berichtet werden","authors":"C. Witt","doi":"10.1159/000504457","DOIUrl":"https://doi.org/10.1159/000504457","url":null,"abstract":"Purpose: It is usual for cancer patients to use complementary and alternative medicines (CAMs) and yet the literature evaluating their efficacy in cancer patients is very limited. The objective of the present study was to report on the nature, frequency of use, and patient-reported outcome of CAMs in a single-center study. Methods: All the consecutive patients treated between November 2017 and June 2018 at the Lucien Neuwirth Cancer Institute (France) were screened. Their reasons for using CAMs and their usage habits were collected. Patients evaluated their benefit. Results: Of the 209 patients screened, 200 patients were included. CAMs ranged from osteopathy, homeopathy, acupuncture, healing touch, magnetism, naturopathy, suction cups, Chinese medicine, reflexology, to hypnosis. CAMs were widely used (n = 166, 83%), the first being osteopathy (n = 99, 49.5%), the second homeopathy (n = 78, 39.0%), and finally acupuncture (n = 76, 38.0%). Whatever the CAM, high satisfaction rates were reported (median satisfaction: 61-81%). CAMs were mainly used to prevent/treat side effects of anticancer treatments (81.2% for healing touch), increase well-being (55.4% for naturopathy), improve the immune system (16.9% for homeopathy), and treat cancer (n = 3, 5.1% for homeopathy). Patients could easily consider using CAMs, as up to 50.8% would have accepted a consultation. Conclusions: The reasons for using CAMs differed among patients. They praised CAMs and kept asking for more information although there is limited evidence about their efficacy in the literature. Thus, prospective randomized controlled trials exploring the safety and efficacy of CAMs in cancer patients are needed.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122201834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastasiertes Pankreaskarzinom: Chirurgen und Internisten müssen Kräfte bündeln 转移性胰腺素医生和内科医生必须裁员
Karger Kompass Onkologie Pub Date : 2019-12-01 DOI: 10.1159/000504463
H. Raab
{"title":"Metastasiertes Pankreaskarzinom: Chirurgen und Internisten müssen Kräfte bündeln","authors":"H. Raab","doi":"10.1159/000504463","DOIUrl":"https://doi.org/10.1159/000504463","url":null,"abstract":"Objective: To assess the perioperative and long-term outcome following pulmonary resection in patients with metachronous metastasis of pancreatic ductal adenocarcinoma (PDAC). Background: Most patients with PDAC relapse or develop tumor spread to secondary organs. Currently, it remains unclear how to proceed with pulmonary metastasis in the metachronous setting. In particular, the role of surgery remains controversial. Methods: Data of patients with pulmonary metachronous metastasis after PDAC collected from 2003 to 2015 in databases of two high-volume pancreatic cancer centers were retrospectively analyzed. Clinical and pathological aspects of primary PDAC as well as the perioperative and long-term outcome following pulmonary metastasectomy (PM) was evaluated, respectively. Patients with synchronous liver metastasis or metastasis to other secondary organs were excluded. Univariate survival analysis was performed. Results: We identified 15 patients undergoing pulmonary resection for suspected metastasis after primary pancreatic resection. Operative and histopathologic evaluation revealed resectable pancreatic pulmonary metastasis in 11 patients (73.3%). The median disease-free survival (DFS) and overall survival (OS) after PM diagnosis was 18 months and 26 months, respectively. The median time to metachronous metastasis (TMM) was 17 months [3-64 months]. Perioperative morbidity was low with only one readmission (8.3%). There was no perioperative mortality. Patients who developed pulmonary metastasis later than 17 months after primary surgery showed better OS compared to those who did earlier (32.2 vs. 14.75 months, p = 0.025). In addition, patients with high-grade tumors had worse survival (12.4 vs. 31 months, p = 0.02). Elevated serum CEA levels or CA 19-9 levels were also not associated with shortened OS. Conclusions: This study suggests that pulmonary metastasectomy after PDAC is safe and effective. Patients with extended DFS after primary pancreatic surgery as well as favorable tumor grading seem to particularly benefit from pulmonary surgery.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129139675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pankreaskarzinom: Neuerungen in der medikamentösen Therapie 胰腺炎药物新发现
Karger Kompass Onkologie Pub Date : 2019-12-01 DOI: 10.1159/000504464
M. Haas
{"title":"Pankreaskarzinom: Neuerungen in der medikamentösen Therapie","authors":"M. Haas","doi":"10.1159/000504464","DOIUrl":"https://doi.org/10.1159/000504464","url":null,"abstract":"Die Therapie des duktalen Adenokarzinoms des Pankreas stellt weiterhin eine große Herausforderung dar. Seit der Einführung von Gemcitabin als Standard-Chemotherapeutikum im Jahr 1997 gab es trotz zahlreicher Therapiestudien nur einen allmählichen, in den letzten Jahren jedoch kontinuierlichen und deutlicheren Fortschritt in der medikamentösen Therapie. In der adjuvanten, postoperativen Situation konnte zuletzt mit modifiziertem FOLFIRINOX (mFOLFIRINOX) eine deutliche Verbesserung gegenüber der bisherigen Standardbehandlung mit Gemcitabin alleine in sämtlichen Effektivitätsendpunkten wie erkrankungsfreies Überleben, Anteil des erkrankungsfreien Überlebens nach 3 Jahren sowie Gesamtüberleben gezeigt werden. Die Wirksamkeit erstreckte sich hier über nahezu alle Subgruppen, insbesondere auch auf Patienten in höherem Tumorstadium (T3 bzw. T4-Tumoren und R1-resezierte Patienten) [1]. Da mFOLFIRINOX mit einer erhöhten Toxizität verbunden ist, bleibt es allerdings (biologisch) jüngeren Patienten vorbehalten, darf in dieser Gruppe jedoch als neuer Therapiestandard angesehen werden. Die in der palliativen Behandlung beobachteten Ansprechraten auf effektivere Chemotherapie Kombinationen wie FOLFIRINOX bzw. Gemcitabin+nab-Paclitaxel von 31,6% bzw. 23,0% führten zur Initiierung zahlreicher Studien zur neoadjuvanten Therapie bei lokal fortgeschrittenen bzw. borderline-resektablen Pankreaskarzinomen.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121458299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ist das Krankenhaus bald das einzige Gesundhaus? 医院会是唯一健康中心吗
Karger Kompass Onkologie Pub Date : 2019-12-01 DOI: 10.1159/000502459
H. Walach
{"title":"Ist das Krankenhaus bald das einzige Gesundhaus?","authors":"H. Walach","doi":"10.1159/000502459","DOIUrl":"https://doi.org/10.1159/000502459","url":null,"abstract":"","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128185363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Absetzkonzepte in der CML: Vertrauensvolle Arzt-Patienten-Beziehung als zentrale Voraussetzung cmi使用的核心概念是信任住院病人关系
Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000501983
Stefanie Jilg
{"title":"Absetzkonzepte in der CML: Vertrauensvolle Arzt-Patienten-Beziehung als zentrale Voraussetzung","authors":"Stefanie Jilg","doi":"10.1159/000501983","DOIUrl":"https://doi.org/10.1159/000501983","url":null,"abstract":"Background: Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of patients who achieved a stable and deep molecular response (DMR) can stop therapy without relapsing. However, most information on treatment cessation was obtained from clinical trials with strict recruiting criteria. Methods: We evaluated the outcome of 25 patients with CML that discontinued TKI therapy in our institute in real-world clinical practice. Results: Of the 25 patients, 76% discontinued therapy in sustained deep molecular response (SDMR) and 24% were in unsustained DMR (UDMR). Discontinuation of therapy due to adverse effects was observed in 5 and 50% of the patients in the SDMR and UDMR groups, respectively. After TKI discontinuation, patients were followed for a median of 24 months. At the time of this analysis, 56% patients had a molecular relapse after a median of 4 months. SDMR and longer treatment duration were associated with lower probability of molecular relapse: 25% in SDMR patients with TKI treatment > 96 months and 85% in UDMR patients with TKI treatment ≤96 months. All relapsed patients promptly resumed TKI therapy and regained at least major molecular response (MMR). Conclusions: Our results suggest that TKI discontinuation is safe outside clinical trials and particularly effective in CML patients who are in SDMR with longer TKI treatment duration.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134267034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ungewöhnlicher Fall von myeloproliferativer Neoplasie mit zwei seltenen klonalen Anomalien 异常情况下,有两种稀有的克隆异常
Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000501922
M. Swaminathan, Keyur P. Patel, Julie Huynh-Lu, Guilin Tang, Zhuang Zuo, Roberto N. Miranda, Srdan Verstovsek
{"title":"Ungewöhnlicher Fall von myeloproliferativer Neoplasie mit zwei seltenen klonalen Anomalien","authors":"M. Swaminathan, Keyur P. Patel, Julie Huynh-Lu, Guilin Tang, Zhuang Zuo, Roberto N. Miranda, Srdan Verstovsek","doi":"10.1159/000501922","DOIUrl":"https://doi.org/10.1159/000501922","url":null,"abstract":"Myeloproliferative Neoplasien (MPN) sind klonale Erkrankungen, die in Philadelphia (Ph)-Chromosom-positive chronische myeloische Leukämie (CML) oder Ph-Chromosom-negative MPN unterteilt werden. Das gleichzeitige Auftreten dieser Krankheitsentitäten ist sehr selten und geht typischerweise mit dem Vorliegen des häufigen BCR-ABL-Fusionstranskripts p190 oder p210 (verantwortlich für die CML) in Kombination mit einer JAK2V617F-Mutation (der häufigsten Driver-Mutation bei Ph-negativen MPN) einher. Da derartige Fälle äußerst selten auftreten, ist unklar, ob sich die Outcomes bei den betroffenen Patienten unterscheiden. Im vorliegenden Artikel berichten wir über den ungewöhnlichen Fall eines Patienten mit Polycythämia vera, ausgelöst durch eine seltene komplexe In-Frame-Deletions-Insertionsmutation im Exon 12 des JAK2-Gens, und CML, ausgelöst durch das seltene BCR-ABL-Fusionstranskript p210 e14a3 (b3a3). Wir beschreiben die klinischen und labordiagnostischen Merkmale, die Ergebnisse der histopathologischen Knochenmarkuntersuchung sowie die Behandlung und das Gesamt-Outcome.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116734285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Next-Generation Sequencing: Neue Möglichkeiten, die Therapie von CML-Patienten zu überwachen 别无选择
Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000502073
H. Link
{"title":"Next-Generation Sequencing: Neue Möglichkeiten, die Therapie von CML-Patienten zu überwachen","authors":"H. Link","doi":"10.1159/000502073","DOIUrl":"https://doi.org/10.1159/000502073","url":null,"abstract":"Background: Kinase domain mutations in BCR-ABL1 are associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Next-generation sequencing (NGS) allows detection of low-level kinase domain mutations, but its relevance in clinical practice remains debated. We aimed to examine the clinical effects of low-level kinase domain mutations identified using NGS in patients with chronic myeloid leukaemia. Methods: In this population-based study, we included consecutive patients newly diagnosed with chronic myeloid leukaemia treated with first-line tyrosine kinase inhibitors, and patients identified at the time of resistance to first-line treatment with imatinib at six institutions (teaching hospitals and district hospitals) in southeast England. We screened patients for BCR-ABL1 kinase domain mutations using NGS, irrespective of patient response to tyrosine kinase inhibitor therapy. When we detected a mutation with NGS, we retrospectively analysed all previous samples to establish the date of first occurrence and subsequent kinetics of the mutant subclone (or subclones). The primary endpoints of this study were progression-free and event-free survival at 5 years. Findings: Between Feb 1, 2007, and Dec 31, 2014, we screened 121 patients with chronic myeloid leukaemia for BCR-ABL1 kinase domain mutation. 99 consecutive patients were newly diagnosed, with available sequential RNA stored. The remaining 22 patients were diagnosed between June 1, 1999, and June 30, 2006, and were screened at the time of resistance to first-line treatment with imatinib. Imatinib was the first-line treatment for 111 patients, nilotinib for seven patients, and dasatinib for three patients. We detected a kinase domain mutation in 25 (21%) of 121 patients. Low-level kinase domain mutations were first identified in 17 (68%) of 25 patients with mutation. For patients with a complete cytogenetic response, 13 (14%) of 93 patients screened had a mutation. Five (71%) of the seven patients with a clinically relevant mutation lost complete cytogenetic response compared with 15 (17%) of 86 patients without a clinically relevant mutation (80 patients without mutation and six patients with a tyrosine kinase inhibitor-sensitive mutation, p=0·0031). Patients harbouring a mutant clone had poorer 5-year progression-free survival (65·3% [95% CI 40·5-81·8] vs 86·9% [75·8-93·2]; p=0·0161) and poorer 5-year event-free survival (22·2% [CI 5·6-45·9] vs 62·0% [50·4-71·6]; p<0·0001) than did patients without a mutation. We identified a kinase domain mutation in four (10%) of 41 patients with samples available at 3 months after starting first-line tyrosine kinase inhibitor treatment; all four subsequently progressed to accelerated phase disease compared with only three (8%) of 37 without a mutation (p<0·0001). Interpretation: NGS reliably and consistently detected early appearance of kinase domain mutations that would not otherwise be detected by Sanger sequencing. F","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"113 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134202451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Die wundersame Zeitvermehrung 有的人就是这样
Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000501762
H. Walach
{"title":"Die wundersame Zeitvermehrung","authors":"H. Walach","doi":"10.1159/000501762","DOIUrl":"https://doi.org/10.1159/000501762","url":null,"abstract":"Zum Beispiel aufstehen und sagen: «Werte Kolleginnen und Kollegen, ich kann aus religiösen Gründen nicht an Sitzungen teilnehmen, die länger als 60 Minuten dauern.» Oder: «Herr Müller, ich verstehe ja, dass Sie in einer schwierigen Situation sind, aber ich glaube, das haben wir letzte Woche schon mal besprochen. Gibt es was Neues?» Dann müssen wir nämlich nicht, wenn die 2-stündige Sitzung aus ist oder der logorrhoeische Herr Müller seine Geschichte zu Ende lamentiert hat, das Gefühl haben, jetzt aber ganz schnell die verlorene Zeit aufholen zu müssen, indem wir E-Mails, Telefonate und Mitarbeitergespräche gleichzeitig abhalten.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129490393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serien abschließen, Studien starten 找几个电视节目,开始研究
Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000502246
N. Neuendorff
{"title":"Serien abschließen, Studien starten","authors":"N. Neuendorff","doi":"10.1159/000502246","DOIUrl":"https://doi.org/10.1159/000502246","url":null,"abstract":"Liebe Leserinnen und Leser, herzlich willkommen! Wir hoffen, Ihnen auch in der aktuellen Ausgabe wieder interessante Themen präsentieren zu dürfen! In der nun vorliegenden Ausgabe schließen wir unsere Serie zur Fertilität mit 2 Beiträgen ab. Herr Prof. Nawroth stellt das FertiProtekt-Netzwerk vor, eine Initiative, die insbesondere den zeitnahen Zugang zur Fertilitätsberatung und – Protektion in den letzten Jahren in Deutschland erheblich verbessert hat. Ein weiterer Schwerpunkt der aktuellen CampusAusgabe stellt das Thema «Testosteronsubstitution nach Orchiektomie» dar. Wir danken Frau Professor Kliesch, Münster, und Herrn Maghaireh, Würzburg, für eine Praxisanleitung zu diesem wichtigen Thema, das insbesondere die Lebensqualität, aber auch viele andere präventivmedizinische Aspekte orchiektomierter Patienten doch entscheidend verbessern kann. Frau Dr. Maria Lipp und Frau Prof. Katharina Hancke, die wir auch schon in den vergangenen Ausgaben für unsere Fertilitätsserie als Autorinnen gewinnen konnten, runden das Thema des Fertilitätserhaltes nun mit einer Übersicht zur Kryokonservierung bei Männern ab. Ein weiterer Themenschwerpunkt stellt die Initiierung klinischer Studien dar. Prof. Richard Schlenk vom Nationalen Tumorzentrum (NCT) in Heidelberg erzählt von seiner Begeisterung für seine Tätigkeit. Nun wünsche ich Ihnen viel Spaß beim Lesen und scheuen Sie sich nicht, uns bei Anregungen oder Kritik zu kontaktieren, vielleicht gibt es ja auch Themenwünsche?","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124006280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信